Delivering better treatments

Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New investigational drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”.

More about Camurus

-0.31% XSTO 2022-01-28 17:00

Financial calendar

  • 2022-02-16 Full Year Report 2021
  • 2022-04-06 Annual Report 2021
  • 2022-05-12 Interim Report January-March 2022
  • 2022-07-15 Interim Report January-June 2022

See more

Press releases

  • 2022-01-13 Camurus announces dosing initiated in Phase 3...
  • 2021-12-30 Change in number of shares and votes in Camurus
  • 2021-12-15 Braeburn receives new Complete Response Letter for...
  • 2021-11-30 The European Medicines Agency accepts application...


Events & Presentations

  • 2022-03-15 Carnegie Healthcare Seminar 2022
  • 2022-06-08 Handelsbanken Nordic Mid/Small Cap Seminar

See more


Transforming treatments for patients with serious and chronic diseases

Camurus' clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development. Our innovative product candidates are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.

See our pipeline


Welcome to the investor relations section. Our ambition is to regularly update shareholders and others on the capital market about Camurus’ status and performance. This is done via press releases, quarterly reports, and presentations at different life science and investment conferences. If you have questions, please don’t hesitate to contact us.

Investor relations

Positive market signals for Buvidal® in Europe

Fredrik Tiberg
CEO Statement


FluidCrystal®- smart and versatile drug delivery

Camurus’ FluidCrystal® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. By combining these with active ingredients with proven efficacy and safety profiles, new patented medicines are developed at significantly lower cost and risk, compared with the development of new medicines.


Camurus AB Ideon Science Park. SE-223 70 Lund, Sweden. Visiting address Ideongatan 1A. 223 62 Lund, Sweden.
Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email addresses General enquiries: info@camurus.com
Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations: ir@camurus.com